Rossella Elisei
#146,738
Most Influential Person Now
Researcher
Rossella Elisei's AcademicInfluence.com Rankings
Download Badge
Physics
Why Is Rossella Elisei Influential?
(Suggest an Edit or Addition)Rossella Elisei's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. (2006) (2006)
- Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. (2015) (1442)
- Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. (2015) (1283)
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial (2014) (1090)
- Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. (2012) (985)
- Cabozantinib in progressive medullary thyroid cancer. (2013) (880)
- Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. (2013) (784)
- BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. (2008) (493)
- Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. (2008) (478)
- Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. (2004) (475)
- Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. (2006) (428)
- Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. (2015) (412)
- Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. (2007) (395)
- Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. (2003) (386)
- Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. (2009) (334)
- RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. (2001) (296)
- Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. (2002) (286)
- Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. (1994) (276)
- Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. (1987) (270)
- Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies (2017) (267)
- Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. (2001) (258)
- Definition and management of radioactive iodine-refractory differentiated thyroid cancer. (2014) (247)
- Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. (2006) (242)
- Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses: a clue to the diagnosis of metastatic differentiated thyroid cancer. (1992) (242)
- BRAFV599E Mutation Is the Leading Genetic Event in Adult Sporadic Papillary Thyroid Carcinomas (2004) (234)
- A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma (2016) (232)
- RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. (2007) (226)
- Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study. (2015) (219)
- Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role. (2009) (213)
- Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. (2010) (207)
- Minimally invasive video-assisted thyroidectomy for papillary carcinoma: a prospective study of its completeness. (2002) (207)
- The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. (2012) (205)
- Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. (2005) (185)
- Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. (2001) (185)
- The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway (2000) (184)
- Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. (2002) (180)
- Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. (2016) (174)
- Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. (2010) (171)
- Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. (1996) (170)
- Combined clinical, thyroid ultrasound and cytological features help to predict thyroid malignancy in follicular and Hϋrthle cell thyroid lesions: results from a series of 505 consecutive patients (2006) (166)
- A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer (2015) (162)
- N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. (2000) (156)
- Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement. (2013) (154)
- Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. (2012) (152)
- A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine‐refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment (2015) (151)
- Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients. (2001) (151)
- Thyroid autoantibodies in thyroid cancer: incidence and relationship with tumour outcome. (1988) (151)
- BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. (2008) (150)
- BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. (2004) (147)
- Clinical and biologic behavior of bone metastases from differentiated thyroid carcinoma. (1989) (143)
- Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies (2018) (139)
- 2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer (2019) (138)
- Treatment of advanced thyroid cancer with targeted therapies: ten years of experience. (2016) (138)
- Thyroid carcinoma in thyrotoxic patients treated by surgery (1988) (133)
- RET/PTC Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma (2012) (131)
- Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. (2014) (129)
- Anaplastic thyroid cancer: prevalence, diagnosis and treatment. (2008) (123)
- RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. (2004) (121)
- Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. (2010) (114)
- The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma. (2007) (111)
- Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. (2002) (111)
- Structural studies of the thyrotropin receptor and Gs alpha in human thyroid cancers: low prevalence of mutations predicts infrequent involvement in malignant transformation. (1996) (110)
- A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). (2011) (108)
- Targeted Therapy in Thyroid Cancer: State of the Art. (2017) (104)
- RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) (2011) (103)
- European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. (2019) (101)
- The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single center. (2012) (101)
- An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. (2012) (97)
- DIAGNOSIS OF ENDOCRINE DISEASE: Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper (2014) (95)
- Detection of thyroid-stimulating antibody using Chinese hamster ovary cells transfected with cloned human thyrotropin receptor. (1993) (94)
- Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. (2009) (91)
- Routine serum calcitonin measurement in the evaluation of thyroid nodules. (2008) (90)
- Obesity and the risk of papillary thyroid cancer: a pooled analysis of three case-control studies. (2014) (89)
- Surgical treatment of low- and intermediate-risk papillary thyroid cancer with minimally invasive video-assisted thyroidectomy. (2009) (88)
- Modifications in the papillary thyroid cancer gene profile over the last 15 years. (2012) (87)
- Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer. (2002) (84)
- Genetic and Clinical Features of Multiple Endocrine Neoplasia Types 1 and 2 (2012) (84)
- A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates. (2009) (84)
- Genome-wide association study on differentiated thyroid cancer. (2013) (84)
- Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for ret gene mutations. (1995) (81)
- Medullary thyroid carcinoma (MTC) and RET proto-oncogene: mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. (2013) (80)
- Genetic and epigenetic alterations of the cyclin‐dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas (1998) (80)
- Medullary thyroid cancer. An immunohistochemical and humoral study using six separate antigens. (1991) (78)
- Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma (2017) (78)
- Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. (2007) (76)
- Lymphocyte and immature dendritic cell infiltrates in differentiated, poorly differentiated, and undifferentiated thyroid carcinoma. (2007) (74)
- Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing (2019) (74)
- Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial. (2013) (73)
- Advances in the follow-up of differentiated or medullary thyroid cancer (2012) (73)
- Expression of thyrotropin receptor (TSH-R), thyroglobulin, thyroperoxidase, and calcitonin messenger ribonucleic acids in thyroid carcinomas: evidence of TSH-R gene transcript in medullary histotype. (1994) (72)
- Involvement of protein kinase Cepsilon (PKCepsilon) in thyroid cell death. A truncated chimeric PKCepsilon cloned from a thyroid cancer cell line protects thyroid cells from apoptosis. (1999) (72)
- Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer. (2013) (72)
- Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1. (2003) (71)
- Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer (2016) (71)
- Patient Age-Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid Cancer. (2017) (71)
- 2012 European Thyroid Association Guidelines for Genetic Testing and Its Clinical Consequences in Medullary Thyroid Cancer (2012) (70)
- Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. (2017) (68)
- Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center. (2020) (67)
- The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer (2017) (66)
- New and old knowledge on differentiated thyroid cancer epidemiology and risk factors. (2012) (64)
- Medullary and papillary tumors are frequently associated in the same thyroid gland without evidence of reciprocal influence in their biologic behavior. (2004) (64)
- Acute exogenous TSH administration stimulates leptin secretion in vivo. (2010) (62)
- Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition. (2004) (61)
- Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. (2019) (59)
- Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up. (2013) (59)
- In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer. (2011) (58)
- A JOINT STATEMENT FROM THE AMERICAN THYROID ASSOCIATION. (2021) (58)
- BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment. (2018) (58)
- Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. (2019) (57)
- RET protein expression has no prognostic impact on the long-term outcome of papillary thyroid carcinoma. (2001) (57)
- Conditional apoptosis induced by oncogenic ras in thyroid cells. (2000) (57)
- European Thyroid Association Guidelines for Genetic Testing and Its Clinical Consequences in Medullary Thyroid Cancer (2013) (56)
- Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma (2012) (56)
- Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow-up of differentiated thyroid cancer patients. (2004) (56)
- A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT). (2014) (54)
- Expression analysis of facilitative glucose transporters (GLUTs) in human thyroid carcinoma cell lines and primary tumors (2008) (53)
- Video-assisted central compartment lymphadenectomy in a patient with a positive RET oncogene: initial experience (2005) (53)
- Thyroid consequences of the Chernobyl nuclear accident (1999) (52)
- Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer. (2012) (52)
- Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. (2017) (51)
- Molecular biology studies on mesothelioma tumor samples: preliminary data on H-ras, p21, and SV40. (1995) (51)
- Clinically unpredictable prognostic factors in the outcome of medullary thyroid cancer. (2007) (50)
- Thyroid autoantibodies and thyroid function in subjects exposed to Chernobyl fallout during childhood: evidence for a transient radiation-induced elevation of serum thyroid antibodies without an increase in thyroid autoimmune disease. (2008) (47)
- All-trans-retinoic acid treatment inhibits the growth of retinoic acid receptor beta messenger ribonucleic acid expressing thyroid cancer cell lines but does not reinduce the expression of thyroid-specific genes. (2005) (46)
- Establishment of a non‐tumorigenic papillary thyroid cell line (FB‐2) carrying the RET/PTC1 rearrangement (2002) (46)
- Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimens. (2003) (45)
- New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double RET mutations (2016) (45)
- Novel genome-wide association study-based candidate loci for differentiated thyroid cancer risk. (2014) (44)
- Measurement of cAMP accumulation in Chinese hamster ovary cells transfected with the recombinant human TSH receptor (CHO-R): a new bioassay for human thyrotropin (1993) (44)
- Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer? (2015) (44)
- Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-2′-deoxycytidine and retinoic acid (2009) (43)
- Identification of rapid turnover transcripts overexpressed in thyroid tumors and thyroid cancer cell lines: use of a targeted differential RNA display method to select for mRNA subsets. (1997) (42)
- Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer. (2012) (42)
- Somatostatin in medullary thyroid cancer. In vitro and in vivo studies (1989) (41)
- Studies with recombinant autoepitopes of thyroid peroxidase: evidence suggesting an epitope shared between the thyroid and the gastric parietal cell. (1990) (39)
- Treatment with drugs able to reduce iodine efflux significantly increases the intracellular retention time in thyroid cancer cells stably transfected with sodium iodide symporter complementary deoxyribonucleic acid. (2006) (39)
- Papillary Thyroid Carcinoma With Rare Exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience. (2016) (39)
- A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): Final survival analysis for the FACT trial. (2011) (38)
- Efficacy of cabozantinib (Cabo) in medullary thyroid cancer (MTC) patients with RAS or RET mutations: Results from a phase III study. (2013) (38)
- Expression of p21 ras protein as a prognostic factor in papillary thyroid cancer. (1994) (37)
- RET proto-oncogene mutations in thyroid carcinomas: Clinical relevance (2000) (37)
- BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer. (2018) (37)
- Final overall survival analysis of EXAM, an international, double-blind, randomized, placebo-controlled phase III trial of cabozantinib (Cabo) in medullary thyroid carcinoma (MTC) patients with documented RECIST progression at baseline. (2015) (37)
- Postoperative Thyroglobulin and Neck Ultrasound in the Risk Restratification and Decision to Perform 131I Ablation. (2016) (36)
- Higher intratumoral expression of CD1a, tryptase, and CD68 in a follicular variant of papillary thyroid carcinoma compared to adenomas: correlation with clinical and pathological parameters. (2011) (35)
- Lack of evidence supporting the presence of mRNA for the thyrotropin receptor in extra-ocular muscle (1993) (35)
- CDKN1B V109G polymorphism a new prognostic factor in sporadic medullary thyroid carcinoma. (2011) (35)
- Management of Medullary Thyroid Cancer. (2019) (34)
- Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations (2019) (34)
- Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer (2016) (33)
- Evidences that the polymorphism Pro‐282‐Ala within the tumor suppressor gene WWOX is a new risk factor for differentiated thyroid carcinoma (2011) (32)
- Recommendations for post-surgical thyroid ablation in differentiated thyroid cancer: a 2015 position statement of the Italian Society of Endocrinology (2015) (32)
- Simian virus 40-like sequences from early and late regions in human thyroid tumors of different histotypes. (2003) (32)
- Calcitonin estimation in patients with nodular goiter and its significance for early detection of MTC: european comments to the guidelines of the American Thyroid Association (2013) (29)
- Updated overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the phase 3 DECISION trial. (2014) (29)
- A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer (2021) (28)
- Congenital hypothyroidism due to a new deletion in the sodium/iodide symporter protein (2003) (28)
- A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC). (2012) (27)
- Demonstration of the existence of the alternatively spliced form of thyroid peroxidase in normal thyroid. (1991) (27)
- Interventional bronchoscopy in the treatment of tracheal obstruction secondary to advanced thyroid cancer (2006) (26)
- T cell responses to orbital antigens in thyroid‐associated ophthalmopathy (1994) (26)
- BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma. (2019) (26)
- Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial (2020) (26)
- Changing Trend of Thyroglobulin Antibodies in Patients With Differentiated Thyroid Cancer Treated With Total Thyroidectomy Without 131I Ablation. (2018) (26)
- Video assisted prophylactic thyroidectomy and central compartment nodes clearance in two RET gene mutation adult carriers (2004) (25)
- Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities (2021) (25)
- Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life. (2017) (25)
- Novel genetic variants in differentiated thyroid cancer and assessment of the cumulative risk (2015) (25)
- Thyroid and Parathyroid Tumors (2013) (25)
- Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer. (2015) (25)
- Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response. (2019) (24)
- Safety and quality of life data from an Italian expanded access program of lenvatinib for treatment of thyroid cancer. (2020) (24)
- Retinoic acid receptor β2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2′-deoxycytidine treatment (2008) (24)
- RET/PTC3 rearrangement and thyroid differentiation gene analysis in a struma ovarii fortuitously revealed by elevated serum thyroglobulin concentration. (2005) (23)
- Influence of human body composition on serum peak thyrotropin (TSH) after recombinant human TSH administration in patients with differentiated thyroid carcinoma. (2005) (23)
- RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases (2018) (23)
- Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience (2018) (22)
- Galectin-3 is highly expressed in nonencapsulated papillary thyroid carcinoma but weakly expressed in encapsulated type; comparison with Hector Battifora mesothelial cell 1 immunoreactivity. (2007) (22)
- Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma (2012) (21)
- FoxP3 expression in papillary thyroid carcinoma: a possible resistance biomarker to iodine 131 treatment. (2014) (21)
- Medullary thyroid cancer secreting carbohydrate antigen 19-9 (Ca 19-9): a fatal case report. (2013) (21)
- Obesity as a risk factor for thyroid cancer (2020) (21)
- Expression of cAMP response element-binding protein and sodium iodide symporter in benign non-functioning and malignant thyroid tumours. (2003) (20)
- A Comprehensive Meta-analysis of Case–Control Association Studies to Evaluate Polymorphisms Associated with the Risk of Differentiated Thyroid Carcinoma (2016) (20)
- Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland (2016) (20)
- TPO genetic variants and risk of differentiated thyroid carcinoma in two European populations (2013) (20)
- Anaplastic thyroid cancer therapy: dream or reality? (2012) (19)
- Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer. (2019) (18)
- Thyroid papillary carcinoma: preliminary evidence for a germ-line single nucleotide polymorphism in the Fas gene. (2004) (18)
- Thyroglobulin autoantibodies as surrogate biomarkers in the management of patients with differentiated thyroid carcinoma. (2014) (17)
- Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line (2012) (17)
- 2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer? (2021) (17)
- Analysis of circulating tumor DNA does not improve the clinical management of patients with locally advanced and metastatic papillary thyroid carcinoma (2018) (17)
- Muscle autoantigens in thyroid associated ophthalmopathy: The limits of molecular genetics (1993) (17)
- Role of RET codonic mutations in the surgical management of medullary thyroid carcinoma in pediatric age multiple endocrine neoplasm type 2 syndromes. (2010) (17)
- Runs of homozygosity and inbreeding in thyroid cancer (2016) (16)
- Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib (2021) (16)
- New breakpoints in both the H4 and RET genes create a variant of PTC‐1 in a post‐Chernobyl papillary thyroid carcinoma (2000) (15)
- Fifty Years After the First Description, MEN 2B Syndrome Diagnosis Is Still Late: Descriptions of Two Recent Cases. (2018) (15)
- DICER1 somatic mutations strongly impair miRNA processing even in benign thyroid lesions (2019) (15)
- Effects of radioiodine treatment for differentiated thyroid cancer on testis function (2015) (15)
- A new germline RET mutation apparently devoid of transforming activity serendipitously discovered in a patient with atrophic autoimmune thyroiditis and primary ovarian failure. (2004) (15)
- Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism. (2021) (15)
- Effect of age and lenvatinib treatment on overall survival for patients with 131I-refractory differentiated thyroid cancer in SELECT. (2015) (14)
- Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer (2021) (14)
- Follicular-derived neoplasms: Morphometric and genetic differences (2013) (14)
- Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma (2018) (14)
- Potential impact of BMI on the aggressiveness of presentation and clinical outcome of Differentiated Thyroid Cancer. (2019) (13)
- How to manage patients with differentiated thyroid cancer and a rising serum thyroglobulin level. (2014) (13)
- Post-surgical ablation of thyroid residues with radioiodine in Ukrainian children and adolescents affected by post-Chernobyl differentiated thyroid cancer (2001) (13)
- BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer. (2021) (13)
- Proteinuria is a late-onset adverse event in patients treated with cabozantinib (2020) (13)
- Features and outcome of differentiated thyroid carcinoma associated with Graves’ disease: results of a large, retrospective, multicenter study (2020) (13)
- Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma. (2019) (13)
- Exploratory analysis of outcomes for patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-RDTC) receiving open-label Sorafenib post-progression on the phase III decision trial (2015) (13)
- Post-surgical follow-up of differentiated thyroid cancer (1995) (12)
- Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer (2016) (12)
- Rare diseases in clinical endocrinology: a taxonomic classification system (2015) (12)
- Expression of calcitonin gene-related peptide in medullary thyroid cancer (1992) (12)
- Epidemiology of Simultaneous Medullary and Papillary Thyroid Carcinomas (MTC/PTC): An Italian Multicenter Study (2019) (12)
- Management of endocrine disease: Papillary thyroid microcarcinoma: towards an active surveillance strategy. (2021) (11)
- Location of functioning metastases from differentiated thyroid carcinoma by simultaneous double isotope acquisition of I-131 whole body scan and bone scan (2004) (11)
- Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group. (2015) (11)
- Impact of Advanced Age on the Clinical Presentation and Outcome of Sporadic Medullary Thyroid Carcinoma (2020) (11)
- Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA) (2022) (10)
- Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up (2020) (10)
- mRECIST criteria to assess recurrent thyroid carcinoma treatment response after radiofrequency ablation: a prospective study (2018) (10)
- Risk of Differentiated Thyroid Carcinoma and Polymorphisms within the Susceptibility Cancer Region 8q24 (2013) (10)
- Molecular Alterations in Relation to Histopathological Characteristics in a Large Series of Pediatric Papillary Thyroid Carcinoma from a Single Institution (2021) (10)
- Molecular profiles of papillary thyroid tumors have been changing in the last decades: how could we explain it? (2014) (10)
- Ret Oncogene and Thyroid Carcinoma (2014) (10)
- Significant response of medullary thyroid cancer choroidal metastases to highly selective RET inhibitor selpercatinib: a case report. (2021) (10)
- Recombinant human TSH (rhTSH) in 2009: new perspectives in diagnosis and therapy. (2009) (10)
- Association between CYP2E1 polymorphisms and risk of differentiated thyroid carcinoma (2016) (10)
- Ultrasound features and risk stratification systems to identify medullary thyroid carcinoma. (2021) (10)
- 1033PSUBGROUP ANALYSES OF A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF LENVATINIB (E7080) IN PATIENTS WITH 131I-REFRACTORY DIFFERENTIATED THYROID CANCER. (2014) (9)
- Poorly Differentiated and Anaplastic Thyroid Cancer: Insights into Genomics, Microenvironment and New Drugs (2021) (9)
- Prognostic and predictive factors correlated with treatment outcomes for radioactive iodine-refractory differentiated thyroid cancer (RAI-RDTC) patients receiving Sorafenib or placebo on the phase III decision trial (2015) (9)
- Thyroid cancer and COVID-19: experience at one single thyroid disease referral center (2021) (9)
- Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer (2021) (9)
- Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey (2020) (9)
- Identification of two distinct molecular subtypes by digital RNA counting of "non-invasive follicular tumour with papillary-like nuclear features (NIFTP)" (2017) (9)
- Less than 2% of the Low- and Intermediate-Risk Differentiated Thyroid Cancers Show Distant Metastases at Post-Ablation Whole-Body Scan (2018) (9)
- Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma. (2016) (9)
- Detection of metastases from differentiated thyroid cancer by different imaging techniques (neck ultrasound, computed tomography and [18F]-FDG positron emission tomography) in patients with negative post-therapeutic 131I whole-body scan and detectable serum thyroglobulin levels (2014) (9)
- Nonthyroidal second primary malignancies in differentiated thyroid cancer patients: Is the incidence increased comparing to the general population and could it be a radioiodine therapy consequence? (2020) (9)
- The polymorphism rs2480258 within CYP2E1 is associated with different rates of acrylamide metabolism in vivo in humans (2018) (8)
- Medullary thyroid carcinoma in children. (2014) (8)
- Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the phase III DECISION trial. (2014) (8)
- Incidental versus clinically evident thyroid cancer: A 5‐year follow‐up study (2013) (8)
- Ca19.9 positivity and doubling time are prognostic factors of mortality in patients with advanced medullary thyroid cancer with no evidence of structural disease progression according to RECIST. (2020) (8)
- Role of YAP-1 in Thyroid Tumor Progression and Outcome (2017) (8)
- Role of Prophylactic Central Compartment Lymph Node Dissection on the Outcome Of Patients With Papillary Thyroid Carcinoma and Synchronous Ipsilateral Cervical Lymph Node Metastases. (2020) (8)
- Thyroid nodule and differentiated thyroid cancer management in pregnancy. An Italian Association of Clinical Endocrinologists (AME) and Italian Thyroid Association (AIT) Joint Statement for Clinical Practice. (2010) (8)
- Somatic Ret Indels In Sporadic Medullary Thyroid Cancer: Prevalence And Response To Selpercatinib. (2022) (7)
- Thyroid Cancer in Ukraine After the Chernobyl Accident: Incidence, Pathology, Treatment, and Molecular Biology (2009) (7)
- rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer (2008) (7)
- [ 18F]-FDG-PET/CT correlates with the response of radiorefractory thyroid cancer to lenvatinib and patients' survival. (2021) (7)
- CDKN 1 B V 109 G polymorphism a new prognostic factor in sporadic medullary thyroid carcinoma (2011) (7)
- DELAYED 131-I FIRST TREATMENT AFTER SURGERY HAS NO IMPACT ON THE MEDIAN TERM OUTCOME OF PATIENTS WITH INTERMEDIATE RISK DIFFERENTIATED THYROID CANCER. (2019) (7)
- Surgical Management of Medullary Thyroid Carcinoma in Pediatric Age. (2016) (7)
- Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates (2021) (7)
- Inherited variants in genes somatically mutated in thyroid cancer (2017) (7)
- Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine (2022) (7)
- mRNA and miRNA expression profiling of follicular variant of papillary thyroid carcinoma with and without distant metastases (2019) (6)
- Final overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib in the phase 3 DECISION trial: An exploratory crossover adjustment analyses (2016) (6)
- Multiethnic genome‐wide association study of differentiated thyroid cancer in the EPITHYR consortium (2020) (6)
- Tall cell percentage alone in PTC without aggressive features should not guide patients' clinical management. (2021) (6)
- Medullary Thyroid Cancer: Diagnosis and Management (2006) (6)
- Whole Tumor Capsule Is Prognostic of Very Good Outcome in the Classical Variant of Papillary Thyroid Cancer. (2021) (5)
- Efficacy and safety of lenvatinib for the treatment of patients with 131I-refractory differentiated thyroid cancer with and without prior VEGF-targeted therapy. (2015) (5)
- Renal complications and quality of life in postsurgical hypoparathyroidism: a case–control study (2021) (5)
- Radiation-induced thyroid diseases (2011) (5)
- Circulating Neuron-Specific Enolase in Medullary Thyroid Cancer (1986) (5)
- Lung Recurrence of Papillary Thyroid Cancer Diagnosed With Antithyroglobulin Antibodies After 10 Years From Initial Treatment (2018) (5)
- Core Needle Biopsy Can Early and Precisely Identify Large Thyroid Masses (2022) (5)
- Clinical case seminar in pediatric thyroid disease. (2014) (5)
- Biology and Clinical Application of the Ms Gene (2003) (5)
- First report of benign track seeding after robot-assisted transaxillary thyroid surgery. (2020) (5)
- A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer (2022) (5)
- EXTENSIVE CLINICAL EXPERIENCE Association of BRAF V600E Mutation with Poor Clinicopathological Outcomes in 500 Consecutive Cases of Papillary Thyroid Carcinoma (2007) (5)
- Incidental occurrence of metastatic medullary thyroid carcinoma in a patient with multiple endocrine neoplasia type 1 carrying germline MEN1 and somatic RET mutations (2017) (5)
- Systemic treatment of advanced, metastatic, medullary thyroid carcinoma (2021) (5)
- Lenvatinib Administered via Nasogastric Tube in Poorly Differentiated Thyroid Cancer (2019) (5)
- Calcitonin receptor expression in medullary thyroid carcinoma (2017) (4)
- Use of low-dose radioiodine ablation for Graves’ orbitopathy: results of a pilot, perspective study in a small series of patients (2018) (4)
- Pharmacodynamic biomarkers of outcomes in the phase III study of lenvatinib in 131I-refractory differentiated thyroid cancer (SELECT). (2015) (4)
- Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer (DTC): The phase III DECISION trial (2014) (4)
- Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer. (2021) (4)
- Patients with Indeterminate Thyroid Nodules at Cytology and Cancer at Histology Have a More Favorable Outcome Compared with Patients with Suspicious or Malignant Cytology. (2018) (4)
- Analysis of tumor growth rate for radioiodine (RAI)-refractory differentiated thyroid cancer patients receiving placebo and/or sorafenib in the phase III DECISION study. (2015) (4)
- Nutrition in Advanced Thyroid Cancer Patients (2022) (4)
- 2022 European Thyroid Association Guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma (2022) (4)
- Management and follow-up of differentiated thyroid cancer not submitted to radioiodine treatment: a systematic review. (2020) (4)
- Identification of Two Distinct Molecular Subtypes of Non-Invasive Follicular Neoplasm with Papillary-Like Nuclear Features by Digital RNA Counting. (2017) (4)
- Transfection with the cDNA of the human thyrotropin receptor of a poorly differentiated rat thyroid cell line (FRT) (1996) (4)
- Markers of cell-proliferation as prognostic factors in differentiated thyroid-cancer. (1993) (3)
- Clinical–Pathological Features and Treatment Outcome of Patients With Hobnail Variant Papillary Thyroid Carcinoma (2022) (3)
- Studies with Recombinant Autoepitopes of Thyroid Peroxidase (1991) (3)
- No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH. (2020) (3)
- Chylous effusions in advanced medullary thyroid cancer patients treated with selpercatinib. (2022) (3)
- Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade (2021) (3)
- LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer. (2022) (3)
- Thyroid diseases around Chernobyl: from autoimmune diseases to malignant tumors (2002) (3)
- Clinical Activity and Pharmacokinetics (PK) of Cabozantinib (XL184) in Patients with Progressive Medullary Thyroid Carcinoma (MTC) (2012) (3)
- Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit (2022) (3)
- Involvement of Protein Kinase Cε (PKCε) in Thyroid Cell Death (1999) (3)
- Pre- And Post-Operative Circulating Tumoral Dna In Patients With Medullary Thyroid Carcinoma. (2022) (2)
- Comunicare con la persona con cancro della tiroide in progressione (2017) (2)
- 1927TiP LIBRETTO-531: Selpercatinib in patients with treatment (Tx)-naïve RET-mutant medullary thyroid cancer (MTC) (2020) (2)
- Using The Cancer Genome Atlas data to refine the 8th edition of the American Joint Committee on Cancer staging for papillary thyroid carcinoma (2020) (2)
- Differential expression of RET isoforms in normal thyroid tissues, papillary and medullary thyroid carcinomas (2019) (2)
- KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease (2017) (2)
- Assessing mPTC Progression during Active Surveillance: Volume or Diameter Increase? (2021) (2)
- Polymorphisms within the RET proto-oncogene and risk of sporadic medullary thyroid carcinoma. (2020) (2)
- Genetic heterogeneity of medullary thyroid carcinoma (2016) (2)
- Diagnostic Applications of Nuclear Medicine: Thyroid Tumors (2017) (2)
- Clinical Management of a Patient with a Locally Recurrent Medullary Thyroid Cancer and Asymptomatic Slowly Progressing Distant Metastases (2020) (2)
- New insight in mRNA and protein expression of glucose transporters (GLUT) in human thyroid carcinoma cell lines (2007) (2)
- CLINICAL VALIDATION OF IMMUNORADIOMETRIC ASSAY FOR MEASURING SERUM THYROGLOBULIN IN ANTI-THYROGLOBULIN AUTOANTIBODY POSITIVE SERA IN PATIENTS WITH THYROID CANCER (1987) (2)
- RET point mutations in Thyroid Carcinoma (2011) (2)
- BRAF mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer (2008) (2)
- Thyroid nodule and differentiated thyroid cancer management in pregnancy. An Italian Association of Clinical Endocrinologists (AME) and Italian Thyroid Association (AIT) Joint Statement for Clinical Practice (2010) (2)
- Multiple endocrine neoplasia type 2 syndromes (MEN 2): Results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes (European Journal of Endocrinology 163 (301-308)) (2010) (2)
- A Phase II Trial of the Multi-Targeted Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer (MTC) (2012) (2)
- Thyroglobulin changes are highly dependent on TSH in low-risk DTC patients not treated with 131I. (2020) (2)
- Trends in thyroid function testing, neck ultrasound, thyroid fine needle aspiration, and thyroidectomies in North-eastern Italy (2021) (2)
- Symptomatic and asymptomatic biliary disorders during lenvatinib treatment for advanced thyroid cancer is an underestimated problem. (2020) (1)
- BRAF(V600E) mutations are correlated with a lower expression of both NIS and TPO mRNA expression in papillary thyroid cancer (PTC) (2007) (1)
- Low-Risk Differentiated Thyroid Cancer with BRAFV600E mutation is more difficult to cure than negative cases: a 5-year follow-up study. (2011) (1)
- Indocyanine green fluorescence and near-infrared autofluorescence may improve post-thyroidectomy parathyroid function. (2022) (1)
- Re: “Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem” by Nervo et al. (2020) (1)
- Radionuclide Therapy of Thyroid Tumors (2016) (1)
- A Comparison of the ATA, NCCN, ETA, and BTA Guidelines for the Management of Medullary Thyroid Cancer (2016) (1)
- A New MEN2 Syndrome with Clinical Features of Both MEN2A and MEN2B Associated with a New RET Germline Deletion (2020) (1)
- Prognostic significance of BRAF mutation in patients affected by papillary thyroid carcinoma with a follow up of 20 years (2007) (1)
- Reply to the Letter to the Editor by Sollini M et al. (2016) (1)
- GENETIC SCREENING OF RET CAN IDENTIFY NEW MUTATIONS EVEN AFTER 20 YEARS (2013) (1)
- Cabozantinib: an orphan drug for thyroid cancer (2015) (1)
- Firm mass in thyroid of an elderly patient: not always cancer. (2020) (1)
- Active Surveillance in RET Gene Carriers Belonging to Families with Multiple Endocrine Neoplasia (2021) (1)
- Limited Accuracy of Pan-Trk Immunohistochemistry Screening for NTRK Rearrangements in Follicular-Derived Thyroid Carcinoma (2022) (1)
- Pros and cons of an aggressive initial treatment with surgery and radioiodine treatment in minimally invasive follicular thyroid carcinoma (2023) (1)
- Pro64His (rs4644) polymorphism within galectin-3 is a risk factor of differentiated thyroid carcinoma and affects the transcriptome of thyrocytes engineered via CRISPR/Cas9 system. (2020) (1)
- Incidence of Anti-Thyroid Autoantibodies in Thyroid Cancer Patients (1987) (1)
- Polygenic susceptibility to papillary thyroid cancer: detection of the main genetic signature in Italian patients (2019) (1)
- Identification of housekeeping genes useful for the normalization of rna in studies of gene expression in thyroid carcinomas (2006) (1)
- A noninferiority trial of cabozantinib (C) comparing 60mg vs 140mg orally per day to evaluate the efficacy and safety in patients (pts) with progressive, metastatic medullary thyroid cancer (MTC). (2018) (1)
- with Minimally Invasive Video-Assisted Thyroidectomy Surgical Treatment of Low- and Intermediate-Risk Papillary Thyroid Cancer (2009) (1)
- The Molecular Signature More Than the Site of Localization Defines the Origin of the Malignancy (2019) (1)
- Failure to use measurement of megalin secretory components complexed with serum thyroglobulin as a tool to identify metastases after surgery in papillary thyroid cancer (2004) (1)
- Tumor growth rate analysis of progression-free survival (PFS) and overall survival (OS) for thyroid cancer patients receiving placebo or sorafenib in the phase 3 DECISION trial (2016) (1)
- Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade (2021) (1)
- Thyroidectomies in Italy: A population-based national analysis from 2001 to 2018. (2022) (1)
- Molecular Characterization of Thyroid Peroxidase Epitopes (1990) (1)
- V804M RET MUTATION AND VANDETANIB RESPONSE IN METASTATIC MEDULLARY THYROID CANCER (2017) (1)
- Esami diagnostici nel sospetto di carcinoma midollare della tiroide (2021) (1)
- Role of Thyroglobulin, Neck Ultrasound, Thyroglobulin Antibodies Trend and Diagnostic Whole Body Scan in the Management of Differentiated Thyroid Cancer Patients with Persistent Thyroglobulin Antibodies (2016) (1)
- Response to Letter: "Postoperative Thyroglobulin and Neck Ultrasound in the Risk Restratification and Decision to Perform 131I Ablation". (2017) (1)
- RET mutated C-cells proliferate more rapidly than non-mutated neoplastic cells (2021) (1)
- Predictive Biomarkers in Thyroid Cancer (2022) (1)
- Medullary Thyroid Cancer: Diagnosis and Non Surgical Management (2018) (1)
- Identification of a novel germ-line point mutation of the ret gene (Met848Thr) in a patient affected by medullary thyroid carcinoma and castlemans syndrome (2006) (0)
- Risk factors for renal calcifications and determinants of hypercalciuria in patients with chronic, post-surgical hypoparathyroidism (2022) (0)
- Italian Guidelines For The Management Of Non-Functioning Benign And Locally Symptomatic Thyroid Nodules. (2023) (0)
- A patient with MEN1 and end-stage chronic kidney disease due to Alport syndrome: Decision making on the eligibility of transplantation. (2017) (0)
- Overview Targeted Therapy in Thyroid Cancer : State of the Art (2018) (0)
- Ciglitazone induces cell growth inhibition in a medullary thyroid carcinoma cell line (TT) likely by an increase of PPARgamma expression (2003) (0)
- Basal calcitonin as guide for an early and safe thyroid surgery in RET gene carriers (2022) (0)
- Simian virus 40-like DNA sequences in human thyroid tumors of different histotypes (2003) (0)
- Congenital hypothyroidism due to a novel deletion in the NIS gene (2003) (0)
- Contents Vol. 1, 2012 (2013) (0)
- BRAFV600E mutation is an indipendent predictive prognostic factor for persistent/recurrent disease in low risk differentiated Thyroid cancer patients: a 5 year follow-up study. (2012) (0)
- European thyroid association guideline on the management of pediatric thyroid nodules and thyroid carcinoma (2022) (0)
- Comparison between serum calcitonin (CT) levels following Pentagastrin (Pg) and Calcium (CA) stimulus (2007) (0)
- A novel fusion RET/PTC3 involving NCOA4 and RET genes in a pediatric case of Papillary Thyroid Carcinoma (2015) (0)
- Comparison of serum calcitonin and neck ultrasound sensitivities in identifying medullary thyroid carcinoma (2022) (0)
- Hand-foot syndrome: a frequent but rarely severe adverse event in patients with thyroid cancer treated with lenvatinib (2023) (0)
- , Post-surgical thyroid remnant ablation with 131-I therapy in patients with differentiated thyroid cancer (DTC): the role of diagnostic tracer dose (2003) (0)
- RET/PTC rearrangements in Belarus, Ukrainian and Russian pos Chernobyl thyroid tumors (2003) (0)
- Medullary Thyroid Cancer (2019) (0)
- C Cell neoplasia (2009) (0)
- LBA30COMPREHENSIVE ANALYSIS OF SERUM BIOMARKER AND TUMOR GENE MUTATION ASSOCIATED WITH CLINICAL OUTCOMES IN THE PHASE 3 STUDY OF (E7080) LENVATINIB IN DIFFERENTIATED CANCER OF THE THYROID (SELECT) (2014) (0)
- 5 Years Follow Up Of Thyroglobulin (Tg), Thyroglobulin Antibodies (Tgab) And Neck Ultrasound (Nus) In Patients With Papillary Thyroid Microcarcinoma (Mptc) Treated With Total Thyroidectomy But Not Ablated With 131I (2016) (0)
- Central Neck Dissection Cannot Be Avoided In Medullary Thyroid Cancer (MTC) On The Basis Of Presurgical Serum Calcitonin (CT) (2017) (0)
- Adrenal insufficiency in thyroid cancer patients treated with tyrosine kinase inhibitors and detected by ACTH stimulation test. (2023) (0)
- RET Copy Number Alteration in Medullary Thyroid Cancer Is a Rare Event Correlated with RET Somatic Mutations and High Allelic Frequency (2020) (0)
- Characterization of three winding transformers for the reduction of switching mode power supply conducted emission (2003) (0)
- A new grading system for medullary thyroid cancer (2022) (0)
- Prognostic value of polymorphisms and somatic RET proto-oncogene mutations in sporadic medullary thyroid carcinoma (MTC) (2007) (0)
- Usefulness of molecular analysis of BRAF mutation and RET/PTC rearrangements in fine needle aspiration (FNA) of thyroid nodules with nondiagnostic cytology (2006) (0)
- Outcome of post Chernobyl papillary thyroid carcinomna treated by surgery , radioiodine and tsh soppressive therapy. (1998) (0)
- Qualità della vita nei pazienti con microcarcinoma papillare della tiroide in funzione del trattamento: tiroidectomia totale con o senza terapia radiometabolica ablativa (2020) (0)
- SP134PROTEINURIA IS A LATE ONSET ADVERSE EVENT IN PATIENTS TREATED WITH CABOZANTINIB: A SINGLE CENTER EXPERIENCE (2018) (0)
- Outcome of sporadic medullary thyroid cancer (MTC) patients with a biochemical persistent disease after initial treatment (2022) (0)
- Partial redifferentiation of thyroid carcinoma cell lines treated with decitabine and retinoic acid (2007) (0)
- Effect of age on the efficacy and safety of lenvatinib for the treatment of 131i-refractory differentiated thyroid cancer in the phase 3 select study (2014) (0)
- Biological and molecular markers for diagnosis, follow-up and prognosis of patients affected by thyroid cancer. (2008) (0)
- Predictive factors of short and long-term vandetanib response in locally advanced or metastatic medullary thyroid cancer: a single center experience (2019) (0)
- IS8. head and neck cancer (2012) (0)
- 957: Inherited variants in genes somatically mutated in thyroid cancer (2014) (0)
- MON-524 Prospective Evaluation of Patients with Encapsulated Classical Variant of Papillary Thyroid Cancer and Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): Have They A Similar Prognosis? (2020) (0)
- Novel somatic mutations in sporadic MTC (spMTC); clinical utility of NGS in precision medicine (2022) (0)
- Ret somatic mutations are not an early event in the tumoral transformation of sporadic medullary thyroid cancer (2012) (0)
- Subject Index Vol. 1, 2012 (2013) (0)
- Diagnosing Advanced Versus Early-Stage Hepatocellular Carcinoma (2012) (0)
- Response to Letter to the Editor From Green and Gosmanov: “Tall Cell Percentage Alone in PTC Without Aggressive Features Should not Guide Patients’ Clinical Management” (2022) (0)
- AssociationBetween BRAFV600EMutationand MortalityinPatientsWithPapillaryThyroidCancer (2013) (0)
- 13th National Congress of the Italian Association of Nuclear Medicine and Molecular Imaging (AIMN), Rimini (Italy), 2–5 March 2017 (2017) (0)
- Characterization of facilitative glucose transporters (GLUT) in human thyroid carcinoma cell lines (2007) (0)
- Current perspectives on the management of patients with advanced RET-driven thyroid cancer in Europe (2023) (0)
- Small neck recurrences in patients with differentiated thyroid cancer (DTC) are accurately diagnosed by the means of ultrasonography (US) and fine needle aspiration biopsy (FNAB) (2003) (0)
- Authors’ Response: Should Serum Calcitonin Be Routinely Measured in Patients with Thyroid Nodules—Will the Law Answer before Endocrinologists Do? (2004) (0)
- Clinicopathological and epidemiological features of thyroid cancer patients intended to initiate systemic therapy (2022) (0)
- 6000 Oral Abstract Session , Sun , 8 : 00 AM-11 : 00 AM Efficacy of cabozantinib ( Cabo ) in medullary thyroid cancer ( MTC ) patients with RAS or RET mutations : Results from a phase III study (2013) (0)
- The prognostic role of chromosomal gains and loss in sporadic medullary thyroid carcinoma (2022) (0)
- Clinical impact of molecular techniques for the presurgical diagnosis of differentiated thyroid cancer diagnosis (2017) (0)
- All-trans Retinoic Acid treatment inhibits the growth of RARb mRNA expressing thyroid cancer cell lines but does not re-induce the expression of thyroid specific genes (2004) (0)
- Np 63 α and YB-1 functional interaction regulates proliferation and survival of normal and transformed keratinocytes (2013) (0)
- NIS mRNA and protein expression in thyroid and non thyroid carcinoma (2003) (0)
- Cervical lymph nodes metastases in differentiated thyroid cancer: impact on clinical outcome (2022) (0)
- Expression gene profile may be useful for the diagnosis of thyroid malignancies (2007) (0)
- The role of 18F-DOPA-PET/CT in medullary thyroid cancer patients with biochemical incomplete response (2023) (0)
- Thyroglobulin Antibodies (TgAb) Titer Spontaneously Decrease Until The Negativization Or Stabilization In Most Of Cases Of Papillary Thyroid Microcarcinoma (mPTC) Treated With Total Thyroidectomy But Not Ablated With 131I (2017) (0)
- Initial therapy of differentiated thyroid carcinoma: an update on surgery and radioiodine (2004) (0)
- Congenital hypothyroidism due to a novel mutation in the NIS gene (2003) (0)
- Low risk differentiated thyroid carcinoma (DTC) can be safely treated with thyroidectomy alone: real-life experience in a medium-long term follow-up (2022) (0)
- Optimizing time of prophylactic surgery in ret gene carriers on the basis of serum calcitonin (2009) (0)
- HUMORAL MARKERS FOR THYROID-CARCINOMA IN CLINICAL-PRACTICE (1991) (0)
- L’ANALISI GENETICA DI CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE RIVELA LA LORO NATURA CASUALE (2013) (0)
- C’è ancora indicazione alla terapia radioablativa con 131-I nel carcinoma tiroideo differenziato a basso rischio? (2017) (0)
- I CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE HANNO ORIGINE GENETICA INDIPENDENTE (2014) (0)
- Correlazione genotipo-fenotipo nelle MEN 2: stato dell’arte dopo 15 anni di conoscenze (2010) (0)
- Carcinoma anaplastico della tiroide: nuovi orizzonti terapeutici (2021) (0)
- Ruolo putativo di H4 come gene oncosoppressore nella patogenesi del carcinoma papillare della tiroide (2003) (0)
- Studi in vitro del trattamento con acido retinoico di linee cellulari di carcinoma tiroideo umano anaplastico, scarsamente differenziato, follicolare e midollare (2003) (0)
- Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato (2016) (0)
- Prevalenza di mutazioni di BRAF e riarrangiamenti RET/PTC e TRK in una serie di carcinomi papillari della tiroide (2004) (0)
- Ruolo delle tecniche di sequenziamento di ultima generazione nella gestione del paziente con carcinoma tiroideo (2021) (0)
- Impatto dell’analisi di sequenza multigenica avanzata Thyroseq sulla diagnosi di cancro nei noduli tiroidei con atipie di incerto significato e/o lesioni follicolari a citologia indeterminata (2015) (0)
- Tiroidectomia profilattica nelle neoplasie endocrine multiple di tipo 2A (2005) (0)
- I tempi della tiroidectomia nella MEN2 (2021) (0)
- Carcinoma differenziato della tiroide: nuovi approcci diagnostici e terapeutici (2008) (0)
- Eterogeneità genetica del carcinoma tiroideo (2020) (0)
- Influenza dell’avanzare dell’età sulla formazione dei noduli tiroidei, sull’evoluzione multinodulare e sul rischio neoplastico (2016) (0)
- La scintigrafia con 99mTecnezio-metossi-isobutil-isonitrile è una metodica utile per caratterizzare il rischio di malignità nei noduli tiroidei a citologia indeterminata (2016) (0)
- Nuove indicazioni all’impiego del TSH umano ricombinante (rhTSH) e basse attività di 131I nella radioablazione del residuo tiroideo post-chirurgico (2013) (0)
- Diagnosi genetica del carcinoma midollare della tiroide: implicazioni diagnostiche e terapeutiche (2004) (0)
- La gestione multidisciplinare delle metastasi ossee nel carcinoma tiroideo (2021) (0)
- Carcinoma della tiroide (2011) (0)
- La terapia chirurgica del carcinoma midollare della tiroide in età pediatrica nell'ambito delle sindromi MEn2: tiroidectomia profilattica versus tiroidectomia curativa (2006) (0)
- Il ciglitazone induce inibizione della crescita in cellule di carcinoma midollare della tiroide (TT) verosimilmente dovuta ad un aumentata espressione di PPAR gamma (2004) (0)
- Incidentaloma surrenalico: dalla identificazione alla scelta terapeutica (2012) (0)
- Nuovi farmaci inibitori selettivi di RET (selpercatinib e pralsetinib) nei pazienti con carcinoma midollare della tiroide avanzato (2021) (0)
- Studi in vitro del trattamento con acido retinico di linee di carcinoma tiroideo umano anaplastico, poco differenziato, follicolare e midollare (2004) (0)
- Biopsia liquida nel cancro della tiroide: utilità e fattibilità (2023) (0)
- La tempistica dell’intervento di tiroidectomia totale nei portatori di mutazioni del gene RET potrebbe essere personalizzata e programmata con sicurezza sulla base dei livelli sierici di calcitonina: 18 anni di esperienza in un singolo centro (2012) (0)
- Carcinoma differenziato della tiroide radioiodio-refrattario in progressione trattato con lenvatinib (2021) (0)
- Ablazione del residuo tiroideo post chirurgico con rhTSH e 30 mCi. (2010) (0)
- Un caso di MEN2B con anomalie scheletriche multiple (2016) (0)
- Il carcinoma tiroideo: nuove prospettive terapeutiche (2014) (0)
- , Descrizione della prima mutazione omozigote germinale di RET (Ala883->Thr) che non determina l'insorgenza del carcinoma midollare della tiroide in condizioni di eterozigosi (2003) (0)
- Alterazioni genomiche e trascrittomiche che caratterizzano il carcinoma scarsamente differenziato e anaplastico della tiroide (2016) (0)
- Diagnosi per immagini istologiche, immunoistochimiche e sonografiche di un raro caso di plasmocitoma scarsamente differenziato della tiroide (2020) (0)
- La mutazione V599E dell'oncogene BRAF rappresenta l'alterazione genetica più frequente nei carcinomi papillari della tiroide sporadici dell'adulto (2003) (0)
- Follow-up dei pazienti e dei carrier di mutazioni del gene MEN2 (2022) (0)
- Carcinoma tiroideo e gravidanza (2013) (0)
- Fenotipo misto MEN2A/MEN2B da nuova mutazione germinale di RET: prima descrizione clinico-genetica e iconografia (2020) (0)
- L’ mRNA dei recettori per HGF e EGF (c-Met e EGFR) e’ iperespresso nei tumori papillari della tiroide (2004) (0)
- Utilità della ricerca della mutazione di BRAF nel tumore primitivo di pazienti affetti da carcinoma papillare della tiroide a basso rischio. (2010) (0)
- Il profilo delle mutazioni somatiche nella variante hobnail del carcinoma papillare della tiroide (2017) (0)
- Reply to J.-F. Chatal et al (2012) (0)
- Increased Risk of Renal Complications in Patients with Chronic Postsurgical Hypoparathyroidism Treated with Conventional Therapy (2017) (0)
- 1 CDKN 1 B V 109 G Polymorphism a New Prognostic Factor in Sporadic Medullary Thyroid Carcinoma (2010) (0)
- After a median follow-up of 3.7 years, patients with low-risk thyroid cancer prepared for postoperative remnant ablation with either L-T 4 withdrawal or rhTSH stimulation have comparable rates of thyroid remnant ablation and tumor recurrence or persistent disease. (2009) (0)
- Impact of energy-based devices in pediatric thyroid surgery. (2022) (0)
- Usefulness of calcitonin (CT) measurement in wash-out fluid from fine needle aspiration biopsy in thyroid nodules of patients with dectectable serum CT (2007) (0)
- Demethylating treatment with azacytidine induces retinoic acid receptor RAR beta expression in human thyroid cancer cells (2006) (0)
- Correction to: Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer (2021) (0)
- MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children (2020) (0)
- Motesanib difosfato nel cancro tiroideo differenziato progressivo (2008) (0)
- Correction: Inherited variants in genes somatically mutated in thyroid cancer (2018) (0)
- The phenotype correlated with RET V804 germline mutation is characterized by the presence of medullary thyroid cancer alone (2022) (0)
- ARG982CYS is a new variant of the RET proto-oncogene: is it a polymorphism or a transforming mutation? (2012) (0)
- Renal complications in patients with chronic postoperative hypoparathyroidism treated with oral calcium and active vitamin D metabolites (2017) (0)
- TKI related adverse events in patients with progressive and metastatic thyroid carcinoma: a retrospective analysis of our experience with cabozantinib during EXAM and EXAMINER clinical trial (2022) (0)
- Timing of total thyroidectomy in RET gene carriers < 18 years of age (2013) (0)
- The prognostic role of forkhead transcription factor FOXP3 expression in papillary thyroid cancer (2011) (0)
- MON-486 Polygenic Susceptibility to Papillary Thyroid Cancer in Italian Subjects (2020) (0)
- Iconography : Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma (2019) (0)
- Supplementary Material for: Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer (2016) (0)
- Lenvatinib treatment in the real clinical practice of progressive, radioiodine-refractory differentiated thyroid carcinoma: analysis of a big series followed in a single center (2019) (0)
- Prevalence of papillary thyroid cancer (PTC) in patients affected by medullary thyroid cancer (MTC) (2003) (0)
- The stage of differentiated thyroid cancer at diagnosis is significantly more advanced in children than in adolescent (2003) (0)
- Interventional Bronchoscopy in the Treatment of Tracheal Obstruction Due to Thyroid Cancer (2004) (0)
- BRAF V600E mutations but not RET/PTC rearrangements are correlated with a lower expression of NIS mRNA expression in papillary thyroid cancer (PTC) (2007) (0)
- Development of a pediatric differentiated thyroid carcinoma registry within the EuRRECa project: rationale and protocol (2023) (0)
- Bilateral testicular metastases of medullary thyroid carcinoma in an adult male with multiple endocrine neoplasia 2A syndrome: case report and review of literature (2022) (0)
- A novel germline RET gene mutation (Ala883Thr) causative of MTC only in homozygous condition (2003) (0)
- Genetic signature of differentiated thyroid carcinoma susceptibility: a machine learning approach (2022) (0)
- New insights in the management of differentiated thyroid cancer. (2013) (0)
- Understanding the effect of obesity on papillary thyroid cancer: is there a need for tailored diagnostic and therapeutic management? (2022) (0)
- THYROID NEOPLASIA AND CANCER Influence of Lymphocytic Thyroiditis at Histology and Serum Thyroglobulin Autoantibodies on the Course of Papillary Thyroid Carcinoma (2020) (0)
- Serum bone Gla-protein (osteocalcin) in patients with bone metastases from thyroid cancer (1993) (0)
- Association between CYP2E1 polymorphisms and risk of differentiated thyroid carcinoma (2016) (0)
- Correlation between early and 24th hour 131-I uptake in post-surgical thyroid remnant evaluation (2003) (0)
- Transarterial Radioembolization for the Treatment of Liver Metastases from Medullary Thyroid Cancer: Dose-Response Relationship and Estimate of the Radiobiological α Parameter (2019) (0)
- MON-495 Influence of Lymphocytic Thyroiditis at Histology and Serum Thyroglobulin Autoantibodies on the Course of Papillary Thyroid Carcinoma (2020) (0)
- Management and outcome of bone metastasis from differentiated thyroid carcinoma in the real life: the M.OS.CA.TI. study (2017) (0)
- Follicular thyroid neoplasm with papillary-like nuclear features (NIFT-P) showed peculiar ultrasonographic features compared to follicular variant of papillary thyroid carcinoma (FV-PTC), follicular carcinoma (FTC) and follicular adenoma (FA) (2022) (0)
- Yttrium-90 transarterial radioembolization for liver metastases from medullary thyroid cancer (2022) (0)
- A Patient with an Advanced Medullary Thyroid Cancer and Progressive, Symptomatic Distant Metastases: When to Start Systemic Therapy (2020) (0)
- Classificatore genetico predittivo della benignità di noduli tiroidei a citologia indeterminata (2020) (0)
- Changes in clinical status after second 131I treatment in patients with differentiated thyroid cancer (dtc) not cured with the initial treatment (2022) (0)
- Factors predicting the results of initial treatment (thyroidectomy and thyroid ablation) in patients with differentiated thyroid cancer (2003) (0)
- Radio-iodine refractory thyroid cancer patients: a tailored follow-up based on clinicopathological features. (2023) (0)
- Outcomes of the Tall-Cell Variant of Papillary Thyroid Carcinoma in Patients with Different Ages: A 17-Year Mono-Institutional Experience (2023) (0)
- Radiation-Induced Thyroid Disease (2021) (0)
- IL CARCINOMA MIDOLLARE DELLA TIROIDE SPORADICO E FAMILIARE E MEN (2006) (0)
- Clinical-Pathological and Molecular Evaluation of 451 NIFTP Patients from a Single Referral Center (2022) (0)
- WHOLE EXOME SEQUENCING OF MEDULLARY THYROID CARCINOMA CASES IDENTIFIES 86 VARIATIONS IN GENES POSSIBLY INVOLVED IN TUMORAL TRANSFORMATION (2013) (0)
- TREATMENT WITH DRUGS ABLE TO REDUCE IODINE EFFLUX SIGNIFICANTLY INCREASES THEINTRACELLULAR RETENTION TIME IN THYROID CANCER CELLS STABLY TRANSFECTED WITHSODIUM IODIDE SYMPORTER (NIS) cDNA (2006) (0)
- The polymorphism rs2480258 within CYP2E1 is associated with different rates of acrylamide metabolism in vivo in humans (2018) (0)
- Thyroid autoimmunity, thyroglobulin autoantibodies and thyroid cancer prognosis. (2023) (0)
- Enlargement of a metastatic lymph node from differentiated thyroid cancer after COVID-19 vaccination (2023) (0)
- Bilateral testicular metastases of MTC in an adult male with MEN2A syndrome: case report and review of literature. (2022) (0)
- Multifocality in sporadic and familiar medullary thyroid cancer: analysis of prevalence and possible predictive roles (2022) (0)
- The presence of tall cells, even if (2019) (0)
- Single thyroid nodule (2012) (0)
- Higher RET Gene Expression Levels Do Not Represent anAlternative RET Activation Mechanism in Medullary Thyroid Carcinoma (2021) (0)
- Significant difference between the prevalence of C cell hyperplasia (CCH) in benign thyroid nodules without histological thyroiditis (HT) and in papillary/follicular thyroid cancers (PTC/FTC) at histology (2017) (0)
- AssociationBetween BRAF V 600 EMutationand MortalityinPatientsWithPapillaryThyroidCancer (2013) (0)
- MON-537 Primary Adrenal Insufficiency During Tyrosine Kinase Inhibitors Treatment in Advanced Thyroid Cancer Patients (2020) (0)
- Lymph nodes metastases in differentiated thyroid cancer patients: understanding their impact on the clinical outcome (2022) (0)
- Mutazione V804M di RET nel carcinoma midollare della tiroide e risposta al trattamento con vandetanib (2017) (0)
- BRAFV600E mutation is an indipendent bad prognostic factor for the out come of patients with papillary thyroid carcinoma: a 15-year median follow-up study. (2007) (0)
- Risk of structural recurrence in differentiated thyroid carcinoma (DTC) patients without evidence of disease after initial treatment: insights into risk factors and comparison with american thyroid association guidelines (2022) (0)
- MicroRNA expression profiling of RAS-mutant thyroid tumors with follicular architecture: microRNA signatures to discriminate benign from malignant lesions. (2023) (0)
- Clinical evolution of sporadic medullary thyroid carcinoma with biochemical incomplete response after initial treatment. (2023) (0)
- IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF GERMLINE GENETIC VARIANTS PREDISPOSING TO DIFFERENTIATED THYROID CANCER RISK (2020) (0)
- OR21-01 Pre-Operative Calcitonin Value as a Predictive Factor of Cancer Related Death in Sporadic Medullary Thyroid Carcinoma (2020) (0)
- Novi pristupi u dijagnostici raka štitnjače (2007) (0)
- CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE (2014) (0)
- Body Mass Index and sporadic Medullary Thyroid Cancer: insights from a large series (2023) (0)
- Clinical and biological patterns of bone metastases from differentiated thyroid carcinoma (1989) (0)
- Whole Exome Sequencing of Medullary Thyroid Carcinomas did not identify oncogenic drivers alternative to RET and RAS genes (2015) (0)
- Response to Letter to the Editor: Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian Center. (2020) (0)
- 17-AAG and DIDS increase the iodide retention time in thyroid cancer cells transfected with NIS (2006) (0)
- Genetica del carcinoma anaplastico della tiroide (2022) (0)
- Active surveillance in differentiated thyroid cancer: a strategy applicable to all treatment categories response (2023) (0)
- Runs of homozygosity and inbreeding in thyroid cancer (2016) (0)
- In vitro studies of retnoic acid treatment of human anaplastic, poorly differentiated papillary, follicular and medullary thyroid cancer cell lines (2004) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Rossella Elisei?
Rossella Elisei is affiliated with the following schools:
